Abstract
A significant number of patients radically treated for prostate cancer (PCa) will develop prostate-specific antigen recurrence (27–53%). Localizing the anatomical site of relapse is critical, in order to achieve the optimal treatment management. To date the diagnostic accuracy of standard imaging is low. Several desirable features have been identified for the amino-acid-based PET agent, fluciclovine (18F) including: long 18F half-life which allows more practical use in centers without a cyclotron onsite; acting as a substrate for amino acid transporters upregulated in PCa or associated with malignant phenotype; lacking of incorporation into protein; and limited urinary excretion. Fluciclovine (18F) is currently approved both in USA and Europe with specific indication in adult men with suspected recurrent PCa based on elevated prostate-specific antigen following prior treatment. Lay summary Fluciclovine (18F) is a novel radiotracer for PET imaging, initially developed for neuro-oncology, then tested in a variety of tumors characterized by an increased need of amino acid uptake. Results in prostate cancer were promising. It is currently approved both in USA and Europe with specific indication in adult men with suspected recurrent prostate cancer based on elevated prostate-specific antigen, following prior treatment.
Funding Information
  • Programma di ricerca Regione-Universita

This publication has 64 references indexed in Scilit: